CSTI 500
Alternative Names: AMR-001181; CSTI-500Latest Information Update: 18 Jul 2025
At a glance
- Originator ConSynance Therapeutics
- Class Behavioural disorder therapies; Obesity therapies; Sleep disorder therapies
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Prader-Willi syndrome
Most Recent Events
- 18 Jul 2025 CSTI 500 is still in phase I trial for Prader-Willi-syndrome(In adolescents, In adults) in USA (PO, Capsule) (Consynance Therapeutics pipeline, July 2025)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Prader-Willi-syndrome(In adolescents, In adults) in USA (PO, Capsule)
- 24 Jul 2024 US FDA grants Rare Pediatric Disease Designation (RPDD)for CSTI 500 in Prader-Willi Syndrome (In children, In adolescents)